A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza

Сологуб, Т. В.; Токин, И. И.; Midikari, A. S; Tsvetkov, V. V

doi:10.20953/1729-9225-2017-3-25-32

Cited by 19 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…medication Triazavirin (2-methylsulfanyl-6-nitro [1,2,4]triazolo [5,1-c] [1,2,4]triazin-7-one sodium salt dihydrate) showed a broad spectrum of antiviral action and high efficacy. The medication protects against infection caused by influenza viruses, [6][7][8][9] ARVI, 10 tick-borne encephalitis. 11,12 Triazavirin has been shown to be effective in treating patients with moderate COVID-19.…”

mentioning

confidence: 99%

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

Fedotov

Русинов

Ulomsky

et al. 2021

Chem Heterocycl Comp

View full text Add to dashboard Cite

Nitrogen-containing heterocyclic compounds are the basis of many natural and synthetic biologically active substances. 1 More than two-thirds of the known drugs used in clinical practice contain heterocyclic and, above all, nitrogen-containing fragments within their structure. Over the past decades, the chemistry of aza-heterocycles has received considerable attention due to the wide spectrum of their biological activity and numerous therapeutic applications in medicine.Of nitrogenous heterocycles, azoloazines containing fragments similar to the natural heterocycles purines and pyrimidines are currently of great practical importance. Thus, non-natural nucleosides abacavir, famciclovir, remdesivir are known, which are the products of structural modifications of all the components of the nucleotide exhibiting excellent indicators of antiviral action (Fig. 1). [2][3][4] In addition to the generally accepted nucleoside forms, the azoloazines themselves are relevant in the search for means of combating diseases on a global scale. Nitroazolo- [5,1-c][1,2,4]triazines and nitroazolo [1,5-a]pyrimidines, a new family of antiviral compounds has been found. 5 The

show abstract

mentioning

confidence: 99%

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

Fedotov

Русинов

Ulomsky

et al. 2021

Chem Heterocycl Comp

View full text Add to dashboard Cite

show abstract

“…A number of research studies, including those of preclinical and clinical trials, have revealed that Triazavirin, which can be considered a guanine analogue, possesses pronounced activity against various strains of influenza virus, including H1N1, H3N2, H5N1, H5N2, H9N2, and H7N3 [ 3 , 4 , 5 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ]. Triazavirin has successfully passed three phases of clinical trials, thus proving its clinical efficacy and safety in the treatment of adult patients with confirmed influenza diagnosis, as indicated in the State Register of Pharmaceutical Products for Medical Purposes of Russian Federation [ 3 , 7 , 9 , 60 ].…”

Section: Pharmacological Properties Of Triazavirinmentioning

confidence: 99%

“…Thus, it was shown that Triazavirin (30 people, 750 mg/day) is comparable to Oseltamivir (29 people, 150 mg/day) in clinical efficacy for the treatment of patients with confirmed influenza diagnosis [ 66 ]. Another comparison, of Triazavirin (82 patients, 750 mg/day for 5 days) with Tamiflu (45 patients, 150 mg/day for 5 days), revealed that the times to recovery and the disappearance of fever, headache, and myalgia were shorter in the patience group administered with Triazavirin [ 63 , 64 , 66 , 67 ].…”

Section: Pharmacological Properties Of Triazavirinmentioning

confidence: 99%

Triazavirin—A Novel Effective Antiviral Drug

Чупахин

Русинов

Вараксин

et al. 2022

IJMS

View full text Add to dashboard Cite

This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug.

show abstract

“…On the basis of nitro-containing azoloazinium compounds, employees of Ural Federal University, Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences, and the Research Institute of Influenza of the Ministry of Health of Russia developed a new class of substances -potential drugs with a wide range of antiviral activity [8]. The main representative of this class of compounds is a drug Triazavirin ® (Riamilovir), which is registered in the Russian Federation and successfully used in the treatment of influenza, SARS, COVID-19 [10][11][12][13]. The sodium salt of 3nitro-4-hydroxy-7-methylthio-4H- [1,2,4]triazolo [5,1-c] [1,2,4]triazinide monohydrate (compound 1) is the closest, in structure, compound to the antiviral drug Triazavirin ® and is currently under development as a drug.…”

Section: Introductionmentioning

confidence: 99%

The electrochemical behavior’s character of a potential antiviral drug 3-nitro-4-hydroxy-7-methylthio-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazinide monohydrate

et al. 2022

View full text Add to dashboard Cite

The results of this study of the electrochemical transformation of 3-R-4-hydroxy-1,4-dihydro-7-X-1,2,4-triazolo[5,1-c][1,2,4] obtained by voltammetry are presented. It was found that 3-R-4-hydroxy-1,4-dihydro-7-X-1,2,4-triazolo[5,1-c][1,2,4] derivatives are capable of electrochemical reduction in the potential range of –0.28 to –0.33 V (relative to Ag/AgCl) in Britton–Robinson buffer at pH = 2. The electrochemical behavior of the sodium salt of 3-nitro-4-hydroxy-7-methylthio-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazinide monohydrate (compound 1), which in silico modeling predicted possible biological activity against various tick-borne encephalitis and Coxsackie B3 viruses. At the potentials of the first stage of electroreduction at pH = 2, the main transformation process is the three-electron reduction scheme of the nitro group of compound 1. It was established that compound 1 in an aprotic medium is reduced in ionic form, most likely in the form of an ion pair with the Na+ cation, and in an aqueous medium in the form of a protonated particle. Based on this, a scheme was proposed for the probable electrochemical transformation of the studied compound.

show abstract

A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza

Cited by 19 publications

References 0 publications

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

Pyrimido[1,2-a]benzimidazoles: synthesis and perspective of their pharmacological use

Triazavirin—A Novel Effective Antiviral Drug

The electrochemical behavior’s character of a potential antiviral drug 3-nitro-4-hydroxy-7-methylthio-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazinide monohydrate

Contact Info

Product

Resources

About